Programmed death–ligand 1 expression on direct Pap‐stained cytology smears from non–small cell lung cancer: Comparison with cell blocks and surgical resection specimens
Background Programmed death–ligand 1 (PD‐L1) expression, as assessed by immunohistochemistry (IHC), is used to select patients with non–small cell lung cancer (NSCLC) for anti‐programmed cell death protein 1 (PD‐1)/PD‐L1 therapy. The current study evaluated the feasibility and efficacy of PD‐L1 immu...
Gespeichert in:
| Veröffentlicht in: | Cancer cytopathology 2019-07, Vol.127 (7), p.470-480 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 480 |
|---|---|
| container_issue | 7 |
| container_start_page | 470 |
| container_title | Cancer cytopathology |
| container_volume | 127 |
| creator | Lozano, Maria D. Abengozar‐Muela, Marta Echeveste, José I. Subtil, José Carlos Bertó, Juan Gúrpide, Alfonso Calvo, Alfonso Andrea, Carlos E. |
| description | Background
Programmed death–ligand 1 (PD‐L1) expression, as assessed by immunohistochemistry (IHC), is used to select patients with non–small cell lung cancer (NSCLC) for anti‐programmed cell death protein 1 (PD‐1)/PD‐L1 therapy. The current study evaluated the feasibility and efficacy of PD‐L1 immunostaining and quantitation on direct Papanicolaou‐stained cytological smears compared with formalin‐fixed paraffin‐embedded samples (cytological cell blocks and surgical resection specimens) in NSCLC cases using 2 commercially available assays: the PD‐L1 IHC 22C3 pharmDx assay (Agilent Technologies/Dako, Carpinteria, CA, USA) and the Ventana SP263 Assay (Ventana Medical Systems Inc, Tucson, Arizona).
Methods
PD‐L1 immunostaining using either both or one of the assays was tested in 117 sets of paired samples obtained from 62 NSCLC cases. The tumor proportion score was reported in every case following the recommendations of the International Association for the Study of Lung Cancer (IASLC).
Results
In 57 sets of samples, both PD‐L1 assays were used. Due to the availability of samples, only 1 assay was performed in 3 sets of samples and in 2 cases, only cytology smears were used and tested for both assays. A total of 113 sets of paired samples finally were evaluated; 4 cases could not be studied due to intense nonspecific background staining. A significant concordance between the 2 assays on cytological smears was found. Concordance between paired cytological smears and formalin‐fixed paraffin‐embedded samples was observed in 97.3% of the cases.
Conclusions
The quantification of PD‐L1 expression on direct Papanicolaou‐stained cytology smears is feasible and reliable for both PD‐L1 assays.
The quantification of programmed death–ligand 1 (PD‐L1) expression on a direct Papanicolaou‐stained cytology smear is feasible. In the current study, PD‐L1 testing in cytology appears to be mostly concordant with corresponding histology samples. |
| doi_str_mv | 10.1002/cncy.22155 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2248384021</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2248384021</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3935-20ce1708cb122e75025066f0b4b8c381a06fe703b2ba0c64851369c1399165273</originalsourceid><addsrcrecordid>eNp9kc1qFjEUhgdRbK1uvAAJuBHhq8lJMj_uZPAPinahoKshky8zTZ0k05wZ6ux6CYL34UX1Ssw4tQsXQkjO4snzHniz7DGjx4xSeKG9Xo4BmJR3skNWcbHLc17evZ3hy0H2APGcUlYWwO5nB5yBkBWIw-zXaQx9VM6ZPdkbNZ1dX_0cbK_8njBivo_RINrgSTp7G42eyKkar69-4KSsT3_0MoUh9AtBZ1RE0sXgiA8-adCpYSDapGuYfU-08trEl6QOblTRYlJe2ulsI9oh6G9I1lycY2-1GkjKToFrOo5GW2c8PszudWpA8-jmPco-v3n9qX63O_n49n396mSnecXlDqg2rKClbhmAKSQFSfO8o61oS81LpmjemYLyFlpFdS5KyXheacariuUSCn6UPdu8YwwXs8GpcRbXRZU3YcYGQJS8FBRYQp_-g56HOfq0XaKkkAAFiEQ93ygdA2I0XTNG61RcGkabtcVmbbH502KCn9wo5zYVc4v-rS0BbAMu7WCW_6ia-kP9dZP-BgOkrD4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2254522724</pqid></control><display><type>article</type><title>Programmed death–ligand 1 expression on direct Pap‐stained cytology smears from non–small cell lung cancer: Comparison with cell blocks and surgical resection specimens</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Lozano, Maria D. ; Abengozar‐Muela, Marta ; Echeveste, José I. ; Subtil, José Carlos ; Bertó, Juan ; Gúrpide, Alfonso ; Calvo, Alfonso ; Andrea, Carlos E.</creator><creatorcontrib>Lozano, Maria D. ; Abengozar‐Muela, Marta ; Echeveste, José I. ; Subtil, José Carlos ; Bertó, Juan ; Gúrpide, Alfonso ; Calvo, Alfonso ; Andrea, Carlos E.</creatorcontrib><description>Background
Programmed death–ligand 1 (PD‐L1) expression, as assessed by immunohistochemistry (IHC), is used to select patients with non–small cell lung cancer (NSCLC) for anti‐programmed cell death protein 1 (PD‐1)/PD‐L1 therapy. The current study evaluated the feasibility and efficacy of PD‐L1 immunostaining and quantitation on direct Papanicolaou‐stained cytological smears compared with formalin‐fixed paraffin‐embedded samples (cytological cell blocks and surgical resection specimens) in NSCLC cases using 2 commercially available assays: the PD‐L1 IHC 22C3 pharmDx assay (Agilent Technologies/Dako, Carpinteria, CA, USA) and the Ventana SP263 Assay (Ventana Medical Systems Inc, Tucson, Arizona).
Methods
PD‐L1 immunostaining using either both or one of the assays was tested in 117 sets of paired samples obtained from 62 NSCLC cases. The tumor proportion score was reported in every case following the recommendations of the International Association for the Study of Lung Cancer (IASLC).
Results
In 57 sets of samples, both PD‐L1 assays were used. Due to the availability of samples, only 1 assay was performed in 3 sets of samples and in 2 cases, only cytology smears were used and tested for both assays. A total of 113 sets of paired samples finally were evaluated; 4 cases could not be studied due to intense nonspecific background staining. A significant concordance between the 2 assays on cytological smears was found. Concordance between paired cytological smears and formalin‐fixed paraffin‐embedded samples was observed in 97.3% of the cases.
Conclusions
The quantification of PD‐L1 expression on direct Papanicolaou‐stained cytology smears is feasible and reliable for both PD‐L1 assays.
The quantification of programmed death–ligand 1 (PD‐L1) expression on a direct Papanicolaou‐stained cytology smear is feasible. In the current study, PD‐L1 testing in cytology appears to be mostly concordant with corresponding histology samples.</description><identifier>ISSN: 1934-662X</identifier><identifier>EISSN: 1934-6638</identifier><identifier>DOI: 10.1002/cncy.22155</identifier><identifier>PMID: 31245924</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Immunological - therapeutic use ; B7-H1 Antigen - analysis ; B7-H1 Antigen - antagonists & inhibitors ; B7-H1 Antigen - metabolism ; biomarkers ; Biomarkers, Tumor - analysis ; Biomarkers, Tumor - antagonists & inhibitors ; Biomarkers, Tumor - metabolism ; Carcinoma, Non-Small-Cell Lung - immunology ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Non-Small-Cell Lung - therapy ; cell blocks ; Cellular biology ; cytology ; Feasibility Studies ; Female ; fine‐needle aspiration ; Humans ; Immunohistochemistry ; immunoperoxidase stain ; immunostaining ; Ligands ; lung ; Lung - pathology ; Lung - surgery ; Lung cancer ; Lung Neoplasms - immunology ; Lung Neoplasms - pathology ; Lung Neoplasms - therapy ; Male ; Middle Aged ; non–small cell lung carcinoma (NSCLC) ; Papanicolaou Test ; Paraffin Embedding ; Patient Selection ; Pneumonectomy ; programmed death–ligand 1 (PD‐L1) ; smears ; Tissue Fixation ; Young Adult</subject><ispartof>Cancer cytopathology, 2019-07, Vol.127 (7), p.470-480</ispartof><rights>2019 American Cancer Society</rights><rights>2019 American Cancer Society.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3935-20ce1708cb122e75025066f0b4b8c381a06fe703b2ba0c64851369c1399165273</citedby><cites>FETCH-LOGICAL-c3935-20ce1708cb122e75025066f0b4b8c381a06fe703b2ba0c64851369c1399165273</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncy.22155$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncy.22155$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31245924$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lozano, Maria D.</creatorcontrib><creatorcontrib>Abengozar‐Muela, Marta</creatorcontrib><creatorcontrib>Echeveste, José I.</creatorcontrib><creatorcontrib>Subtil, José Carlos</creatorcontrib><creatorcontrib>Bertó, Juan</creatorcontrib><creatorcontrib>Gúrpide, Alfonso</creatorcontrib><creatorcontrib>Calvo, Alfonso</creatorcontrib><creatorcontrib>Andrea, Carlos E.</creatorcontrib><title>Programmed death–ligand 1 expression on direct Pap‐stained cytology smears from non–small cell lung cancer: Comparison with cell blocks and surgical resection specimens</title><title>Cancer cytopathology</title><addtitle>Cancer Cytopathol</addtitle><description>Background
Programmed death–ligand 1 (PD‐L1) expression, as assessed by immunohistochemistry (IHC), is used to select patients with non–small cell lung cancer (NSCLC) for anti‐programmed cell death protein 1 (PD‐1)/PD‐L1 therapy. The current study evaluated the feasibility and efficacy of PD‐L1 immunostaining and quantitation on direct Papanicolaou‐stained cytological smears compared with formalin‐fixed paraffin‐embedded samples (cytological cell blocks and surgical resection specimens) in NSCLC cases using 2 commercially available assays: the PD‐L1 IHC 22C3 pharmDx assay (Agilent Technologies/Dako, Carpinteria, CA, USA) and the Ventana SP263 Assay (Ventana Medical Systems Inc, Tucson, Arizona).
Methods
PD‐L1 immunostaining using either both or one of the assays was tested in 117 sets of paired samples obtained from 62 NSCLC cases. The tumor proportion score was reported in every case following the recommendations of the International Association for the Study of Lung Cancer (IASLC).
Results
In 57 sets of samples, both PD‐L1 assays were used. Due to the availability of samples, only 1 assay was performed in 3 sets of samples and in 2 cases, only cytology smears were used and tested for both assays. A total of 113 sets of paired samples finally were evaluated; 4 cases could not be studied due to intense nonspecific background staining. A significant concordance between the 2 assays on cytological smears was found. Concordance between paired cytological smears and formalin‐fixed paraffin‐embedded samples was observed in 97.3% of the cases.
Conclusions
The quantification of PD‐L1 expression on direct Papanicolaou‐stained cytology smears is feasible and reliable for both PD‐L1 assays.
The quantification of programmed death–ligand 1 (PD‐L1) expression on a direct Papanicolaou‐stained cytology smear is feasible. In the current study, PD‐L1 testing in cytology appears to be mostly concordant with corresponding histology samples.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents, Immunological - therapeutic use</subject><subject>B7-H1 Antigen - analysis</subject><subject>B7-H1 Antigen - antagonists & inhibitors</subject><subject>B7-H1 Antigen - metabolism</subject><subject>biomarkers</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Biomarkers, Tumor - antagonists & inhibitors</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Carcinoma, Non-Small-Cell Lung - immunology</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Carcinoma, Non-Small-Cell Lung - therapy</subject><subject>cell blocks</subject><subject>Cellular biology</subject><subject>cytology</subject><subject>Feasibility Studies</subject><subject>Female</subject><subject>fine‐needle aspiration</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>immunoperoxidase stain</subject><subject>immunostaining</subject><subject>Ligands</subject><subject>lung</subject><subject>Lung - pathology</subject><subject>Lung - surgery</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - immunology</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>non–small cell lung carcinoma (NSCLC)</subject><subject>Papanicolaou Test</subject><subject>Paraffin Embedding</subject><subject>Patient Selection</subject><subject>Pneumonectomy</subject><subject>programmed death–ligand 1 (PD‐L1)</subject><subject>smears</subject><subject>Tissue Fixation</subject><subject>Young Adult</subject><issn>1934-662X</issn><issn>1934-6638</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1qFjEUhgdRbK1uvAAJuBHhq8lJMj_uZPAPinahoKshky8zTZ0k05wZ6ux6CYL34UX1Ssw4tQsXQkjO4snzHniz7DGjx4xSeKG9Xo4BmJR3skNWcbHLc17evZ3hy0H2APGcUlYWwO5nB5yBkBWIw-zXaQx9VM6ZPdkbNZ1dX_0cbK_8njBivo_RINrgSTp7G42eyKkar69-4KSsT3_0MoUh9AtBZ1RE0sXgiA8-adCpYSDapGuYfU-08trEl6QOblTRYlJe2ulsI9oh6G9I1lycY2-1GkjKToFrOo5GW2c8PszudWpA8-jmPco-v3n9qX63O_n49n396mSnecXlDqg2rKClbhmAKSQFSfO8o61oS81LpmjemYLyFlpFdS5KyXheacariuUSCn6UPdu8YwwXs8GpcRbXRZU3YcYGQJS8FBRYQp_-g56HOfq0XaKkkAAFiEQ93ygdA2I0XTNG61RcGkabtcVmbbH502KCn9wo5zYVc4v-rS0BbAMu7WCW_6ia-kP9dZP-BgOkrD4</recordid><startdate>201907</startdate><enddate>201907</enddate><creator>Lozano, Maria D.</creator><creator>Abengozar‐Muela, Marta</creator><creator>Echeveste, José I.</creator><creator>Subtil, José Carlos</creator><creator>Bertó, Juan</creator><creator>Gúrpide, Alfonso</creator><creator>Calvo, Alfonso</creator><creator>Andrea, Carlos E.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201907</creationdate><title>Programmed death–ligand 1 expression on direct Pap‐stained cytology smears from non–small cell lung cancer: Comparison with cell blocks and surgical resection specimens</title><author>Lozano, Maria D. ; Abengozar‐Muela, Marta ; Echeveste, José I. ; Subtil, José Carlos ; Bertó, Juan ; Gúrpide, Alfonso ; Calvo, Alfonso ; Andrea, Carlos E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3935-20ce1708cb122e75025066f0b4b8c381a06fe703b2ba0c64851369c1399165273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents, Immunological - therapeutic use</topic><topic>B7-H1 Antigen - analysis</topic><topic>B7-H1 Antigen - antagonists & inhibitors</topic><topic>B7-H1 Antigen - metabolism</topic><topic>biomarkers</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Biomarkers, Tumor - antagonists & inhibitors</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Carcinoma, Non-Small-Cell Lung - immunology</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Carcinoma, Non-Small-Cell Lung - therapy</topic><topic>cell blocks</topic><topic>Cellular biology</topic><topic>cytology</topic><topic>Feasibility Studies</topic><topic>Female</topic><topic>fine‐needle aspiration</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>immunoperoxidase stain</topic><topic>immunostaining</topic><topic>Ligands</topic><topic>lung</topic><topic>Lung - pathology</topic><topic>Lung - surgery</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - immunology</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>non–small cell lung carcinoma (NSCLC)</topic><topic>Papanicolaou Test</topic><topic>Paraffin Embedding</topic><topic>Patient Selection</topic><topic>Pneumonectomy</topic><topic>programmed death–ligand 1 (PD‐L1)</topic><topic>smears</topic><topic>Tissue Fixation</topic><topic>Young Adult</topic><toplevel>online_resources</toplevel><creatorcontrib>Lozano, Maria D.</creatorcontrib><creatorcontrib>Abengozar‐Muela, Marta</creatorcontrib><creatorcontrib>Echeveste, José I.</creatorcontrib><creatorcontrib>Subtil, José Carlos</creatorcontrib><creatorcontrib>Bertó, Juan</creatorcontrib><creatorcontrib>Gúrpide, Alfonso</creatorcontrib><creatorcontrib>Calvo, Alfonso</creatorcontrib><creatorcontrib>Andrea, Carlos E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer cytopathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lozano, Maria D.</au><au>Abengozar‐Muela, Marta</au><au>Echeveste, José I.</au><au>Subtil, José Carlos</au><au>Bertó, Juan</au><au>Gúrpide, Alfonso</au><au>Calvo, Alfonso</au><au>Andrea, Carlos E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Programmed death–ligand 1 expression on direct Pap‐stained cytology smears from non–small cell lung cancer: Comparison with cell blocks and surgical resection specimens</atitle><jtitle>Cancer cytopathology</jtitle><addtitle>Cancer Cytopathol</addtitle><date>2019-07</date><risdate>2019</risdate><volume>127</volume><issue>7</issue><spage>470</spage><epage>480</epage><pages>470-480</pages><issn>1934-662X</issn><eissn>1934-6638</eissn><abstract>Background
Programmed death–ligand 1 (PD‐L1) expression, as assessed by immunohistochemistry (IHC), is used to select patients with non–small cell lung cancer (NSCLC) for anti‐programmed cell death protein 1 (PD‐1)/PD‐L1 therapy. The current study evaluated the feasibility and efficacy of PD‐L1 immunostaining and quantitation on direct Papanicolaou‐stained cytological smears compared with formalin‐fixed paraffin‐embedded samples (cytological cell blocks and surgical resection specimens) in NSCLC cases using 2 commercially available assays: the PD‐L1 IHC 22C3 pharmDx assay (Agilent Technologies/Dako, Carpinteria, CA, USA) and the Ventana SP263 Assay (Ventana Medical Systems Inc, Tucson, Arizona).
Methods
PD‐L1 immunostaining using either both or one of the assays was tested in 117 sets of paired samples obtained from 62 NSCLC cases. The tumor proportion score was reported in every case following the recommendations of the International Association for the Study of Lung Cancer (IASLC).
Results
In 57 sets of samples, both PD‐L1 assays were used. Due to the availability of samples, only 1 assay was performed in 3 sets of samples and in 2 cases, only cytology smears were used and tested for both assays. A total of 113 sets of paired samples finally were evaluated; 4 cases could not be studied due to intense nonspecific background staining. A significant concordance between the 2 assays on cytological smears was found. Concordance between paired cytological smears and formalin‐fixed paraffin‐embedded samples was observed in 97.3% of the cases.
Conclusions
The quantification of PD‐L1 expression on direct Papanicolaou‐stained cytology smears is feasible and reliable for both PD‐L1 assays.
The quantification of programmed death–ligand 1 (PD‐L1) expression on a direct Papanicolaou‐stained cytology smear is feasible. In the current study, PD‐L1 testing in cytology appears to be mostly concordant with corresponding histology samples.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31245924</pmid><doi>10.1002/cncy.22155</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1934-662X |
| ispartof | Cancer cytopathology, 2019-07, Vol.127 (7), p.470-480 |
| issn | 1934-662X 1934-6638 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2248384021 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Agents, Immunological - therapeutic use B7-H1 Antigen - analysis B7-H1 Antigen - antagonists & inhibitors B7-H1 Antigen - metabolism biomarkers Biomarkers, Tumor - analysis Biomarkers, Tumor - antagonists & inhibitors Biomarkers, Tumor - metabolism Carcinoma, Non-Small-Cell Lung - immunology Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - therapy cell blocks Cellular biology cytology Feasibility Studies Female fine‐needle aspiration Humans Immunohistochemistry immunoperoxidase stain immunostaining Ligands lung Lung - pathology Lung - surgery Lung cancer Lung Neoplasms - immunology Lung Neoplasms - pathology Lung Neoplasms - therapy Male Middle Aged non–small cell lung carcinoma (NSCLC) Papanicolaou Test Paraffin Embedding Patient Selection Pneumonectomy programmed death–ligand 1 (PD‐L1) smears Tissue Fixation Young Adult |
| title | Programmed death–ligand 1 expression on direct Pap‐stained cytology smears from non–small cell lung cancer: Comparison with cell blocks and surgical resection specimens |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T18%3A10%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Programmed%20death%E2%80%93ligand%201%20expression%20on%20direct%20Pap%E2%80%90stained%20cytology%20smears%20from%20non%E2%80%93small%20cell%20lung%20cancer:%20Comparison%20with%20cell%20blocks%20and%20surgical%20resection%20specimens&rft.jtitle=Cancer%20cytopathology&rft.au=Lozano,%20Maria%20D.&rft.date=2019-07&rft.volume=127&rft.issue=7&rft.spage=470&rft.epage=480&rft.pages=470-480&rft.issn=1934-662X&rft.eissn=1934-6638&rft_id=info:doi/10.1002/cncy.22155&rft_dat=%3Cproquest_cross%3E2248384021%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2254522724&rft_id=info:pmid/31245924&rfr_iscdi=true |